Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil

被引:1
|
作者
El Oumeiri, Bachar [1 ]
Dewachter, Laurence [2 ]
Van de Borne, Philippe [3 ]
Hubesch, Geraldine [2 ]
Melot, Christian [2 ]
Jespers, Pascale [2 ]
Stefanidis, Constantin [1 ]
Mc Entee, Kathleen [2 ]
Vanden Eynden, Frederic [1 ]
机构
[1] Univ Libre Bruxelles ULB, Dept Cardiac Surg, Erasme Univ Hosp, B-1070 Brussels, Belgium
[2] Univ Libre Bruxelles ULB, Fac Med, Lab Physiol & Pharmacol, B-1070 Brussels, Belgium
[3] Univ Libre Bruxelles ULB, Dept Cardiol, Erasme Univ Hosp, B-1070 Brussels, Belgium
关键词
left ventricle; omecamtiv mecarbil; gene expression; apoptosis; metabolism; oxidative stress; NITRIC-OXIDE SYNTHASE; BETA-ADRENERGIC STIMULATION; HEART-FAILURE; ENDOTHELIAL RECEPTOR; INCREASES; LOX-1; PHARMACOLOGY; INFLAMMATION; CONTRIBUTES; SENSITIVITY;
D O I
10.3390/genes14010122
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
To explore the impact of omecamtiv mecarbil (OM) on the gene expression profile in adult male rats. Fourteen male Wistar rats were randomly assigned to a single OM (1.2 mg/kg/h; n = 6) or placebo (n = 8) 30-min infusion. Echocardiography was performed before and after OM infusion. Seven days after infusion, rats were euthanized, and left ventricular (LV) tissues were removed for real-time quantitative polymerase chain reaction (RTq-PCR) experiments. After OM infusion, pro-apoptotic Bax-to-Bcl2 ratio was decreased, with increased Bcl2 and similar Bax gene expression. The gene expression of molecules regulating oxidative stress, including glutathione disulfide reductase (Gsr) and superoxide dismutases (Sod1/Sod2), remained unchanged, whereas the expression of antioxidant glutathione peroxidase (Gpx) increased. While LV gene expression of key energy sensors, peroxisome proliferator activator (Ppar) alpha and gamma, AMP-activated protein kinase (Ampk), and carnitine palmitoyltransferase 1 (Cpt1) remained unchanged after OM infusion, and the expression of pyruvate dehydrogenase kinase 4 (Pdk4) increased. The LV expression of the major myocardial glucose transporter Glut1 decreased, with no changes in Glut4 expression, whereas the LV expression of oxidized low-density lipoprotein receptor 1 (Olr1) and arachidonate 15-lipoxygenase (Alox15) increased, with no changes in fatty acid transporter Cd36. An increased LV expression of angiotensin II receptors AT1 and AT2 was observed, with no changes in angiotensin I-converting enzyme expression. The Kalikrein-bradykinin system was upregulated with increased LV expression of kallikrein-related peptidases Klk8, Klk1c2, and Klk1c12 and bradykinin receptors B1 and B2 (Bdkrb1 and Bdkrb2), whereas the LV expression of inducible nitric oxide synthase 2 (Nos2) increased. LV expression in major molecular determinants involved in calcium-dependent myocardial contraction remained unchanged, except for an increased LV expression of calcium/calmodulin-dependent protein kinase II delta (Cacna1c) in response to OM. A single intravenous infusion of OM, in adult healthy rats, resulted in significant changes in the LV expression of genes regulating apoptosis, oxidative stress, metabolism, and cardiac contractility.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation
    El Oumeiri, Bachar
    Borne, Philippe
    Hubesch, Geraldine
    Herpain, Antoine
    Annoni, Filippo
    Jespers, Pascale
    Stefanidis, Constantin
    Mc Entee, Kathleen
    Vanden Eynden, Frederic
    PHYSIOLOGICAL REPORTS, 2021, 9 (16):
  • [2] The myosin activator omecamtiv mecarbil: a promising new inotropic agent
    Nanasi, Peter, Jr.
    Vaczi, Krisztina
    Papp, Zoltan
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2016, 94 (10) : 1033 - 1039
  • [3] DOSE-DEPENDENT ELECTROPHYSIOLOGICAL EFFECTS OF THE MYOSIN ACTIVATOR OMECAMTIV MECARBIL IN CANINE VENTRICULAR CARDIOMYOCYTES
    Szentandrassy, N.
    Horvath, B.
    Vaczi, K.
    Kistamas, K.
    Masuda, L.
    Magyar, J.
    Banyasz, T.
    Papp, Z.
    Nanasi, P. P.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2016, 67 (04): : 483 - 489
  • [4] Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin
    Morgan, Bradley P.
    Muci, Alexander
    Lu, Pu-Ping
    Qian, Xiangping
    Tochimoto, Todd
    Smith, Whitney W.
    Garard, Marc
    Kraynack, Erica
    Collibee, Scott
    Suehiro, Ion
    Tomasi, Adam
    Valdez, S. Corey
    Wang, Wenyue
    Jiang, Hong
    Hartman, James
    Rodriguez, Hector M.
    Kawas, Raja
    Sylvester, Sheila
    Elias, Kathleen A.
    Godinez, Guillermo
    Lee, Kenneth
    Anderson, Robert
    Sueoka, Sandra
    Xu, Donghong
    Wang, Zhengping
    Djordjevic, Nebojsa
    Malik, Fady I.
    Morgans, David J., Jr.
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (09): : 472 - 477
  • [5] Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure
    Liu, Licette C. Y.
    Dorhout, Bernard
    van der Meer, Peter
    Teerlink, John R.
    Voors, Adriaan A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (01) : 117 - 127
  • [6] Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator
    Caille, Seb
    Allgeier, Alan M.
    Bernard, Charles
    Correll, Tiffany L.
    Cosbie, Andrew
    Crockett, Richard D.
    Cui, Sheng
    Faul, Margaret M.
    Hansen, Karl B.
    Huggins, Seth
    Langille, Neil
    Mennen, Steven M.
    Morgan, Bradley P.
    Morrison, Henry
    Muci, Alexander
    Nagapudi, Karthik
    Quasdorf, Kyle
    Ranganathan, Krishnakumar
    Roosen, Philipp
    Shi, Xianqing
    Thiel, Oliver R.
    Wang, Fang
    Tvetan, Justin T.
    Woo, Jacqueline C. S.
    Wu, Steven
    Walker, Shawn D.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (08) : 1558 - 1567
  • [7] Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure The COSMIC-HF Trial
    Biering-Sorensen, Tor
    Minamisawa, Masatoshi
    Claggett, Brian
    Liu, Jiankang
    Felker, G. Michael
    McMurray, John J. V.
    Malik, Fady I.
    Abbasi, Siddique
    Kurtz, Christopher E.
    Teerlink, John R.
    Solomon, Scott D.
    CIRCULATION-HEART FAILURE, 2020, 13 (12) : E008007
  • [8] Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure
    Mack, Maat
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2024, 32 (04) : 378 - 383
  • [9] Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results
    Nanasi, Peter, Jr.
    Komaromi, Istvan
    Gaburjakova, Marta
    Almassy, Janos
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (15) : 1720 - 1728
  • [10] Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
    El-Oumeiri, Bachar
    Mc Entee, Kathleen
    Annoni, Filippo
    Herpain, Antoine
    Eynden, Frederic Vanden
    Jespers, Pascal
    Van Nooten, Guido
    van de Borne, Philippe
    BMC CARDIOVASCULAR DISORDERS, 2018, 18